LUCD - NASDAQ

Lucid Diagnostics Inc.

LUCD·NASDAQ

$1.02

+0.49%

HealthcareMedical - Devices

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$104.35M

EPS-0.6900

P/E Ratio-1.48

Earnings Date08/12/2026

lucd

Other Non-Current Assets

Last Annual Value

-2.93B

3-Year CAGR

-1283%

5-Year CAGR

-422%

10-Year CAGR

Adjust for Inflation

Lucid Diagnostics Inc. Competitors Analysis of Other Non-Current Assets

LUCD · NASDAQ

Company	Other Non-Current Assets	CAGR 3Y	CAGR 5Y	CAGR 10Y
Lucid Diagnostics Inc. NASDAQ:LUCD	-2.93B	N/A	N/A	N/A
Owlet, Inc. NYSE:OWLT	1.90M	42.6%	23.3%	N/A
Rapid Micro Biosystems, Inc. NASDAQ:RPID	603.00K	-17.0%	-19.4%	N/A
Scilex Holding Company NASDAQ:SCLX	224.64M	1261.5%	234.3%	N/A
Metagenomi, Inc. Common Stock NASDAQ:MGX	6.03M	3.2%	5.9%	N/A
Anika Therapeutics, Inc. NASDAQ:ANIK	9.67M	-32.0%	-13.8%	63.9%
Solana Company NASDAQ:HSDT	267.16M	1140.4%	N/A	N/A
Insight Molecular Diagnostics Inc. NASDAQ:IMDX	7.03M	48.1%	-26.0%	57.5%
LENSAR, Inc. NASDAQ:LNSR	18.96M	141.6%	41.6%	N/A
TScan Therapeutics, Inc. NASDAQ:TCRX	71.35M	120.3%	N/A	N/A
AVITA Medical, Inc. NASDAQ:RCEL	3.73M	9.6%	31.7%	N/A

Lucid Diagnostics Inc. Fair Value Envelope

LUCD · NASDAQ

Our analysis suggests that LUCD has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.02, this represents a potential HIDDEN relative to our calculated worth for Lucid Diagnostics Inc..

HIDDEN

Intrinsic Value

Current Price: $1.02

Related Guides

Blog Categories

Continue your LUCD research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.